Leslie Huszar
Neurology · Vero Beach, FLNPI 1528063492
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 98 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 22 manufacturers, the largest accounting for just 17.9% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $874, 3.7 times the $235 reported in 2021.
Across 98 payments — averaging $24.65 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Eisai Inc.$433
- AbbVie$391
- Lilly USA, LLC$388
- Takeda Pharmaceuticals U.S.A., Inc.$166
- Argenx US, Inc.$149
- Pfizer$144
- plus $745 from 16 others
What the payments were for
- Food & beverage$2,416100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Eisai Inc. | 13 | $433 |
| AbbVie | 15 | $391 |
| Lilly USA, LLC | 16 | $388 |
| Takeda Pharmaceuticals U.S.A., Inc. | 8 | $166 |
| Argenx US, Inc. | 6 | $149 |
| Pfizer | 7 | $144 |
| Alnylam Pharmaceuticals Inc. | 4 | $111 |
| Johnson & Johnson | 4 | $80 |
| Adamas Pharmaceuticals, Inc. | 3 | $69 |
| Corium, LLC | 3 | $61 |
| CSL Behring | 2 | $50 |
| Biohaven Pharmaceutical Holding Company Ltd. | 3 | $49 |
| Bristol Myers Squibb | 2 | $48 |
| Biogen | 2 | $47 |
| Novartis | 2 | $46 |
| Catalyst Pharmaceuticals, Inc. | 1 | $35 |
| Biohaven Pharmaceuticals, Inc. | 2 | $29 |
| Lundbeck LLC | 1 | $29 |
| Sanofi | 1 | $25 |
| Otsuka America Pharmaceutical, Inc. | 1 | $24 |
| GE HealthCare | 1 | $21 |
| Impel Pharmaceuticals Inc. | 1 | $20 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$2,416 in reported general payments places this provider in the 55th percentile of 1,434 neurology providers in Florida.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| PrivigenImmun Glob G(Igg)/Pro/Iga 0-50 | 30 | $229,885 |
| GammaplexImmun Glob G(Igg)/Gly/Iga 0-50 | 14 | $120,624 |
| Gamunex-CImmune Globul G/Gly/Iga Avg 46 | 12 | $112,148 |
| Nurtec OdtRimegepant Sulfate | 25 | $35,599 |
| QuliptaAtogepant | 26 | $27,614 |
| RexultiBrexpiprazole | 16 | $26,281 |
| SymbicortBudesonide/Formoterol Fumarate | 13 | $3,070 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 49 | $2,435 |
| Carbidopa-LevodopaCarbidopa/Levodopa | 51 | $1,704 |
| Zolmitriptan | 13 | $1,629 |
| Baclofen | 56 | $1,489 |
| Levetiracetam | 43 | $1,291 |
| Escitalopram Oxalate | 71 | $1,224 |
| Midodrine Hcl | 20 | $1,164 |
| Lorazepam | 104 | $1,133 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| CSL BehringPrivigen | $50 | $229,88530 claims |
| PfizerNurtec Odt | $144 | $35,59925 claims |
| AbbVieQulipta | $391 | $27,61426 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $24 | $26,28116 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 1,434 neurology providers in Florida.
Other neurology in Vero Beach
- Stuart IsaacsonBoca Raton$3.9M
- Selim BenbadisTampa$2.1M
- Derrick RobertsonTampa$1.8M
- Robert HauserTampa$1.6M
- David RoseTampa$1.4M
- Matthew BakerNaples$1.4M
- Donald NegroskiSarasota$1.4M
- Mark CascioneTampa$1.2M
- Lance KimOcala$1M
- Tuan VuTampa$1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.